Blood-pressure-lowering peptide (FVAPFPEV)
A small peptide that blocks ACE, the enzyme that raises blood pressure, helping to lower it; used only as a lab research tool.
A researcher, an agent, or an algorithm wrote down the sequence and picked a target to hit.
An AI model like OpenFold3 or AlphaFold built a 3D structure and scored how well it fits the binding site.
A second contributor repeated the computation on their own hardware and the scores matched.
Literature-extracted sequence peptide — synthesized for bioassay as documented in linked reference(s)
Fork this card to add platform evidence →
Activity measured in linked reference(s) — IC50/MIC/cytotoxicity data
Fork this card to add platform evidence →
Research directions for this peptide, selected from the current sources — hypotheses you can explore and model. None of it is proven yet; tap any one to see the full thinking.
Why would a slightly longer version of a helpful peptide work worse than the shorter one?
If this holds, it tells researchers exactly where to stop when building peptides that lower blood pressure, so they don't waste effort making fragments that are longer but weaker. It could help narrow the design space for future food-derived blood pressure supplements.
Could a milk-derived peptide lower blood pressure without causing the nagging dry cough that many blood pressure drugs do?
Common ACE-inhibitor drugs cause a persistent dry cough in roughly one in five patients because they affect a specific branch of the enzyme. If this peptide works on a different branch, it might lower blood pressure without that side effect, which could make it a more tolerable option for people who cannot take standard medications.
Can a single change to one building block of a peptide stop your body from breaking it down before it can work?
Most short peptides from food get destroyed in the blood within minutes. If swapping one standard amino acid for a slightly bulkier version stiffens the molecule enough to survive, it could turn a fragile dietary compound into something that behaves more like a real drug, with predictable dosing and lasting effect.
Could a peptide that blocks a blood pressure enzyme also protect the kidneys from slowly scarring over time?
Chronic kidney disease often progresses through scarring driven by local enzyme activity inside the kidney, not just by high blood pressure. If this peptide reaches the kidney and damps that process, it might slow disease in people with early kidney damage even before they develop hypertension, which is a much larger and harder-to-treat group.
What if one food-derived peptide could do the job of two separate drugs that together form a leading heart-failure treatment?
A drug combination that blocks both ACE and neprilysin is already one of the most effective heart-failure treatments available. If this milk peptide turns out to inhibit both enzymes even partially, it could serve as a natural template for developing a single food-based compound with broader cardiovascular benefit, potentially useful for both high blood pressure and heart failure.
Could the reason food peptides sometimes work better in real life than in a lab dish be that they also shift the gut microbiome in a helpful direction?
Gut bacteria that feed on proline-rich fragments can produce short-chain fatty acids, which have their own independent blood-pressure-lowering effect. If this peptide nudges the microbiome that way, it would explain why casein-derived peptides often outperform what their lab measurements predict, and it could point toward combining them with specific dietary fibers to get a stronger, more reliable effect.
▸full evidence table2 metrics
| metric | value | tool |
|---|---|---|
| ipTM | 0.5797842741012573 | boltz-2 |
| ranking score | 0.7965718507766724 | boltz-2 |
▸3-letter notation
▸recipeboltz-2 1.0
| parameter | value |
|---|---|
| model | boltz-2 1.0 |
| weights | — |
| hardware | nvidia_nim_api |
| mlx version | — |
| python | — |
| random seed | — |
| msa strategy | colabfold_nvidia |
| diffusion samples | 1 |
| runtime | — |
| predicted by | mlx@peptide |
| predicted at | 2026-04-25 |
▸citationbibtex
@peptide{pep04730,
sequence = {FVAPFPEV},
target = {ace},
author = {peptidemodel},
year = {2026},
status = {bioassayed}
}